Preliminary testing of two long-acting injectable drugs indicates it might be possible to keep HIV at bay indefinitely with injections every month or two.
Johnson & Johnson and partner ViiV Healthcare, which specializes in HIV drugs, announced results from the first 32 weeks of the planned 96-week study, which combines one drug from each company.
Significant additional testing is needed, but the treatment could eventually be a huge advance over a disease once almost universally fatal
.